Company Registration No. 14614301 (England and Wales)
Millennia Pharma Ltd
Unaudited accounts
for the year ended 31 January 2026
Millennia Pharma Ltd
Statement of financial position
as at 31 January 2026
Intangible assets
522,000
561,000
Tangible assets
9,735
9,525
Cash at bank and in hand
220,107
107,928
Creditors: amounts falling due within one year
(204,490)
(161,038)
Net current assets
186,030
138,221
Total assets less current liabilities
717,765
708,746
Creditors: amounts falling due after more than one year
(721,345)
(802,953)
Net liabilities
(3,580)
(94,207)
Called up share capital
10
10
Profit and loss account
(3,590)
(94,217)
Shareholders' funds
(3,580)
(94,207)
For the year ending 31 January 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
The members have agreed to the preparation of abridged accounts for the year in accordance with Section 444(2A).
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 29 October 2026 and were signed on its behalf by
Mr V H Patel
Director
Company Registration No. 14614301
Millennia Pharma Ltd
Notes to the Accounts
for the year ended 31 January 2026
Millennia Pharma Ltd is a private company, limited by shares, registered in England and Wales, registration number 14614301. The registered office is 11 Bellis Way, Walton-le-Dale, Preston, Lancashire, PR5 4NS, England.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
These financial statements for the year ended 31 January 2026 are the first financial statements that comply with FRS 102 Section 1A Small Entities. The date of transition is 1 February 2024.
The transition to FRS 102 Section 1A Small Entities has resulted in a small number of changes in accounting policies to those used previously.
The nature of these changes and their impact on opening equity and profit for the comparative period are explained in the notes below.
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Fixtures & fittings
20% SL
Intangible fixed assets (including purchased goodwill and patents) are included at cost less accumulated amortisation.
4
Intangible fixed assets
Total
At 1 February 2025
600,000
At 31 January 2026
600,000
Charge for the year
39,000
At 31 January 2026
522,000
At 31 January 2025
561,000
Millennia Pharma Ltd
Notes to the Accounts
for the year ended 31 January 2026
5
Tangible fixed assets
Total
6
Average number of employees
During the year the average number of employees was 14 (2025: 14).